- Home
- PGRE vs SNDX Comparison
PGRE vs SNDX Comparison
Compare PGRE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- SNDX
- Stock Information
- Founded
- PGRE 1978
- SNDX 2005
- Country
- PGRE United States
- SNDX United States
- Employees
- PGRE N/A
- SNDX N/A
- Industry
- PGRE Real Estate Investment Trusts
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- SNDX Health Care
- Exchange
- PGRE Nasdaq
- SNDX Nasdaq
- Market Cap
- PGRE 1.3B
- SNDX 1.1B
- IPO Year
- PGRE 2014
- SNDX 2016
- Fundamental
- Price
- PGRE $6.35
- SNDX $9.48
- Analyst Decision
- PGRE Hold
- SNDX Strong Buy
- Analyst Count
- PGRE 4
- SNDX 11
- Target Price
- PGRE $5.38
- SNDX $35.91
- AVG Volume (30 Days)
- PGRE 2.3M
- SNDX 1.9M
- Earning Date
- PGRE 07-30-2025
- SNDX 07-31-2025
- Dividend Yield
- PGRE 0.55%
- SNDX N/A
- EPS Growth
- PGRE N/A
- SNDX N/A
- EPS
- PGRE N/A
- SNDX N/A
- Revenue
- PGRE $711,729,000.00
- SNDX $43,722,000.00
- Revenue This Year
- PGRE $1.66
- SNDX $426.77
- Revenue Next Year
- PGRE N/A
- SNDX $98.31
- P/E Ratio
- PGRE N/A
- SNDX N/A
- Revenue Growth
- PGRE 49.28
- SNDX N/A
- 52 Week Low
- PGRE $3.75
- SNDX $8.58
- 52 Week High
- PGRE $6.62
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- PGRE 66.88
- SNDX 36.85
- Support Level
- PGRE $6.31
- SNDX $11.00
- Resistance Level
- PGRE $6.62
- SNDX $11.83
- Average True Range (ATR)
- PGRE 0.15
- SNDX 0.58
- MACD
- PGRE -0.06
- SNDX -0.11
- Stochastic Oscillator
- PGRE 60.38
- SNDX 10.31
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.